Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04538950 · ClinicalTrials.gov registry record · Phase 1
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04538950: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT04538950 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04538950, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.
Interventions
- DIAGNOSTIC_TEST PET/CT
- DRUG radioactive drug (tracer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04538950
The ClinicalTrials.gov registry entry for NCT04538950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT is the first listed.
NCT04538950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04538950 about?
NCT04538950 is a clinical study titled "PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy". Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.
What is the current status of trial NCT04538950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-08-14. Estimated completion is 2022-05-19.
What interventions are being tested in trial NCT04538950?
The interventions under investigation include: PET/CT (DIAGNOSTIC_TEST), radioactive drug (tracer) (DRUG).
Who is sponsoring clinical trial NCT04538950?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.